The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $101.35 in the prior trading day, Sarepta Therapeutics Inc (NASDAQ: SRPT) closed at $73.54, down -27.44%. In other words, the price has decreased by -$27.44 from its previous closing price. On the day, 13.39 million shares were traded. SRPT stock price reached its highest trading level at $81.87 during the session, while it also had its lowest trading level at $73.06.
Ratios:
Our goal is to gain a better understanding of SRPT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.18 and its Current Ratio is at 4.20. In the meantime, Its Debt-to-Equity ratio is 0.88 whereas as Long-Term Debt/Eq ratio is at 0.87.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Deutsche Bank on February 11, 2025, initiated with a Hold rating and assigned the stock a target price of $136.
On November 27, 2024, Needham reiterated its Buy rating and also upped its target price recommendation from $205 to $202.
On November 25, 2024, H.C. Wainwright started tracking the stock assigning a Sell rating and target price of $80.H.C. Wainwright initiated its Sell rating on November 25, 2024, with a $80 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 12 ’25 when Nicaise Claude sold 2,491 shares for $99.64 per share. The transaction valued at 248,203 led to the insider holds 27,812 shares of the business.
Nicaise Claude bought 2,491 shares of SRPT for $248,226 on Mar 12 ’25. On Dec 12 ’24, another insider, Wigzell Hans Lennart Rudolf, who serves as the Director of the company, sold 10,500 shares for $124.84 each. As a result, the insider received 1,310,820 and left with 22,840 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SRPT now has a Market Capitalization of 7135740416 and an Enterprise Value of 7123816448. As of this moment, Sarepta’s Price-to-Earnings (P/E) ratio for their current fiscal year is 30.85, and their Forward P/E ratio for the next fiscal year is 5.26. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.33. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.75 while its Price-to-Book (P/B) ratio in mrq is 4.66. Its current Enterprise Value per Revenue stands at 3.745 whereas that against EBITDA is 27.849.
Stock Price History:
The Beta on a monthly basis for SRPT is 0.75, which has changed by -0.41671956 over the last 52 weeks, in comparison to a change of 0.07465422 over the same period for the S&P500. Over the past 52 weeks, SRPT has reached a high of $173.25, while it has fallen to a 52-week low of $97.06. The 50-Day Moving Average of the stock is -33.58%, while the 200-Day Moving Average is calculated to be -41.48%.
Shares Statistics:
The stock has traded on average 884.68K shares per day over the past 3-months and 2335570 shares per day over the last 10 days, according to various share statistics. A total of 96.90M shares are outstanding, with a floating share count of 91.14M. Insiders hold about 6.07% of the company’s shares, while institutions hold 91.30% stake in the company. Shares short for SRPT as of 1740700800 were 5064242 with a Short Ratio of 5.72, compared to 1738281600 on 5053295. Therefore, it implies a Short% of Shares Outstanding of 5064242 and a Short% of Float of 5.45.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
A comprehensive evaluation of Sarepta Therapeutics Inc (SRPT) is underway, with the input of 9.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $2.65, with high estimates of $3.16 and low estimates of $1.74.
Analysts are recommending an EPS of between $13.94 and $4.32 for the fiscal current year, implying an average EPS of $10.45. EPS for the following year is $15.58, with 10.0 analysts recommending between $18.62 and $11.76.
Revenue Estimates
14 analysts predict $692.97M in revenue for the current quarter. It ranges from a high estimate of $736.6M to a low estimate of $640.3M. As of the current estimate, Sarepta Therapeutics Inc’s year-ago sales were $413.46MFor the next quarter, 14 analysts are estimating revenue of $764.54M. There is a high estimate of $925.93M for the next quarter, whereas the lowest estimate is $720.3M.
A total of 20 analysts have provided revenue estimates for SRPT’s current fiscal year. The highest revenue estimate was $3.39B, while the lowest revenue estimate was $2.88B, resulting in an average revenue estimate of $3.13B. In the same quarter a year ago, actual revenue was $1.9BBased on 17 analysts’ estimates, the company’s revenue will be $3.91B in the next fiscal year. The high estimate is $4.4B and the low estimate is $3.16B.
